Oncology Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.

      Venclyxto_UK_R_4C

      By clicking the link(s) above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      By clicking the link(s) above you will leave the AbbVie Pro website and be taken to the meMC PI portal website

      UK-VNCAML-240003  |  April 2024.

      Videos

      Practical management

      Models of Care

      VIALE-A

      Podcasts

      Audio bitesize

      frontiers-top-banner
      frontiers-top-banner

      Episode 1- VIALE-A

      Richard Dillon & Caroline Alvares

      This podcast provides an overview of the VIALE-A study, which was a randomised, double-blind, placebo controlled, Phase 3 study that evaluated the efficacy and safety of Venclyxto plus azacitidine vs azacitidine alone in adult patients with newly-diagnosed AML who were ineligible for intensive chemotherapy.1,2

      Further information from the VIALE-A study can be found here.

      Click here for references

      Episode 2 – Fitness & Frailty

      Richard Dillon & Caroline Alvares

      This podcast discusses assessing fitness and frailty in AML patients and also touches on the pooled post-hoc analysis, which evaluated outcomes of Venclyxto plus azacitidine vs azacitidine alone, across elderly age cohorts in chemotherapy-ineligible patients with newly diagnosed AML.1

      Watch Dr O’Nions video on the AML Highlights from the American Society of Hematology (ASH) 2023 Annual Meeting for further information

      Click here for references

      Episode 3 – TLS prophylaxis

      Richard Dillon & Caroline Alvares

      This podcast provides a brief overview on some key considerations for managing the risk of tumour lysis syndrome (TLS) with Venclyxto in AML.

      Further information on TLS prophylaxis can be found here.

      Click here for references

      Episode 4 – Cycle 1 dosing schedule

      Richard Dillon & Caroline Alvares

      This podcast discusses the dosing of Venclyxto in combination with azacitidine during initiation in cycle 1, including the dose ramp-up phase and some of the monitoring requirements during this period.

      Further information on Venclyxto dosing in AML, including considerations in patients with renal or hepatic impairment can be found here.

      Click here for references

      Episode 5 – Use of anti-microbial prophylaxis

      Richard Dillon & Caroline Alvares

      This podcast takes a look at why anti-infective prophylaxis is considered in AML patients treated with Venclyxto and the impact some anti-infectives, such as anti-fungals have on Venclyxto dosing.

      Further information on drug-drug interactions with Venclyxto in AML can be found here.

      Click here for references

      Episode 6 – Cytopenia Management

      Richard Dillon & Caroline Alvares

      This podcast discusses cytopenia management for patients receiving Venclyxto + azacitidine in AML.

      Further information on cytopenia management for Venclyxto AML patients can be found here.

      Click here for references

      UK-VNCAML-240196  |  November 2024.

      VENCLYXTO in combination with a hypomethylating agent or low-dose cytarabine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.1

      You are advised to read the Prescribing Information and SmPC to evaluate patient suitability for VENCLYXTO. Click here for SmPC and here for Prescribing Information.
      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported.
      Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. 
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      References:

      1. VENCLYXTO Summary of Product Characteristics.
      2. DiNardo CD et al. N Engl J Med. 2020; 383(7): 617-29.
      3. Pratz KW et al. Am J Hematol. 2024; 99(4): 615-624

      References:

      1. Venditti A et al. Blood. 2023; 142 (Supplement 1): 2886.
      2. Reljic T et al. J Geriatr Oncol. 2020; 11(8): 1293–1308.
      3. Bell JA et al. Clin Lymphoma Myeloma Leuk. 2018; 18(7): e303–e14.
      4. VENCLYXTO Summary of Product Characteristics.
      5. Cancer Research UK. Acute myeloid leukaemia (AML) incidence statistics London: Cancer Research UK.
      6. DiNardo CD et al. N Engl J Med. 2020; 383(7): 617-29.
      7. ECOG-ACRIN. ECOG Performance Scale.
      8. Sorror ML et al. Blood. 2005; 106(8): 2912–2919.
      9. Speaker's own experience and practice.

      References:

      1. Venditti A et al. Blood. 2023; 142 (Supplement 1): 2886.
      2. Reljic T et al. J Geriatr Oncol. 2020; 11(8): 1293–1308.
      3. Bell JA et al. Clin Lymphoma Myeloma Leuk. 2018; 18(7): e303–e14.
      4. VENCLYXTO Summary of Product Characteristics.
      5. Cancer Research UK. Acute myeloid leukaemia (AML) incidence statistics London: Cancer Research UK.
      6. Michaelis LC et al. Expert Opin Pharmacother. 2018; 19(8): 865-82.
      7. DiNardo CD et al. N Engl J Med. 2020; 383(7): 617-29.
      8. ECOG-ACRIN. ECOG Performance Scale.
      9. Sorror ML et al. Blood. 2005; 106(8): 2912–2919.
      10. Speaker's own experience and practice.

      References:

      1. VENCLYXTO Summary of Product Characteristics.
      2. Howard SC et al. N Engl J Med. 2011; 364:1844–54.
      3. DiNardo CD et al. N Eng J Med. 2020; 383(7): 617-29
      4. Speaker's own experience and practice.

      References:

      1. VENCLYXTO Summary of Product Characteristics.
      2. Speaker's own experience and practice.

      References:

      1. VENCLYXTO Summary of Product Characteristics.
      2. Cornely OA et al. N Engl J Med.  2007; 356(4): 348-59.
      3. DiNardo CD et al. N Engl J Med. 2020; 383(7): 617-29.
      4. Jonas BA, Pollyea DA. Leukemia. 2019; 33: 2795–2804.
      5. Jonas BA et al. Am J Hematol. 2022 Nov;97(11):E422-E425.
      6. Jonas BA et al. Poster 2846. ASH 62nd; Dec 5-8, 2020; Virtual.
      7. Speaker's own experience and practice.

      References:

      1. VENCLYXTO Summary of Product Characteristics
      2. DiNardo CD et al. N Engl J Med. 2020; 383(7): 617-29.
      3. Pratz KW et al. Am J Hematol. 2024; 99(4): 615-624
      4. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.
      5. Pratz KW et al. Oral Presentation 219. Presented at: 64th American Society of Hematology Annual Meeting; December 10-13, 2022; New Orleans, USA.
      6. Speaker's own experience and practice.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.